Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes

Summary

Primary Objective: To assess the overall safety of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks in patients with type 2 diabetes in Japan Secondary Objective: To assess the effects of lixisenatide once daily treatment in monotherapy over 24 and 52 weeks on: * HbA1c (Glycated hemoglobin A1c) reduction; * Fasting plasma glucose; * Body weight.

Timeline

Start

2013-11

Primary completion

2015-03

Completion

2015-03

Drugs

Indications